Gene therapy trial for diabetic macular edema
Part of Eyes & vision clinical trials.
This study tests a new gene therapy called LX111 for diabetic macular edema (DME) that has not improved enough with previous injections. It aims to see if a single treatment can reduce swelling and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 1 or type 2 diabetes with swelling in the center of the retina (DME).
- Your retinal thickness is at least 300 micrometers in the study eye.
- Your vision in the study eye is between 19 and 73 letters on an eye chart (roughly 20/400 to 20/40).
- You have had anti-VEGF injections in the past year and they helped somewhat.
- You have not had certain other eye treatments recently (like laser, steroid implants, or gene therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection into the eye for adults with diabetic macular edema (DME), a condition where fluid builds up in the retina and blurs vision. The goal is to reduce the need for frequent eye injections and help maintain vision over time.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This study tests an oral medication that may reduce swelling in the retina caused by diabetes. If you have diabetic macular edema affecting your central vision, this trial could help you preserve or improve your sight.
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.